标题
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-09-25
DOI
10.3389/fonc.2019.00953
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
- (2019) David H. Peng et al. Science Translational Medicine
- MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
- (2019) Chih-Shia Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
- (2019) Jong Woo Lee et al. Journal of Thoracic Oncology
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
- (2019) María Teresa Blasco et al. CANCER CELL
- Nf1 loss promotes Kras‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
- (2019) Xiaojing Wang et al. EMBO Molecular Medicine
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
- (2019) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
- (2019) Hengyu Lu et al. MOLECULAR CANCER THERAPEUTICS
- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
- (2019) Haitang Yang et al. Oncogenesis
- c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
- (2018) Manuel Sanclemente et al. CANCER CELL
- MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation
- (2018) Lingtao Jin et al. CANCER CELL
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
- (2018) Gabrielle S. Wong et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Afatinib restrains K-RAS–driven lung tumorigenesis
- (2018) Herwig P. Moll et al. Science Translational Medicine
- The ERBB network facilitates KRAS-driven lung tumorigenesis
- (2018) Björn Kruspig et al. Science Translational Medicine
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Differential Effector Engagement by Oncogenic KRAS
- (2018) Tina L. Yuan et al. Cell Reports
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small-cell Lung Cancer
- (2018) Stéphane Renaud et al. Clinical Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer
- (2018) Shun-Qing Liang et al. ONCOGENE
- SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
- (2018) Carmine Fedele et al. Cancer Discovery
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
- (2018) Francesco Passiglia et al. BRITISH JOURNAL OF CANCER
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
- (2018) Tatsuya Nagano et al. CURRENT CANCER DRUG TARGETS
- Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
- (2018) Marcel Wiesweg et al. ONCOGENE
- Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
- (2018) Shunsuke Kitajima et al. Cancer Discovery
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
- (2017) Monica Mita et al. INVESTIGATIONAL NEW DRUGS
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
- (2017) Rodrigo Romero et al. NATURE MEDICINE
- Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
- (2017) Haiwei Mou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
- (2017) Sehhoon Park et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
- (2016) Stéphane Renaud et al. BRITISH JOURNAL OF CANCER
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- (2016) Vassiliki Papadimitrakopoulou et al. JOURNAL OF CLINICAL ONCOLOGY
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- (2016) Ying-Nan P. Chen et al. NATURE
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
- (2016) H. Kitai et al. Cancer Discovery
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
- (2015) E. Rulli et al. ANNALS OF ONCOLOGY
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
- (2015) Helena A. Yu et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
- (2015) Christina H. Eng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
- (2014) Andrea Viale et al. NATURE
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
- (2013) Sang Min Lim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
- (2013) S. Dearden et al. ANNALS OF ONCOLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
- (2013) M. B. Salt et al. Cancer Discovery
- Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines
- (2012) Steffan Vartanian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)
- (2012) Jacques Cadranel et al. Journal of Thoracic Oncology
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
- (2011) J. Y. Guo et al. GENES & DEVELOPMENT
- C-Raf Is Required for the Initiation of Lung Cancer by K-Ras G12D
- (2011) Florian A. Karreth et al. Cancer Discovery
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
- (2009) Takashi Matozaki et al. CANCER SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search